Physician profile
Paul Andre Bilder
NPI 1275663247
$3,486.42
in general payments reported to CMS, 2019-2025
23 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $444 · 2021: $346 · 2022: $606 · 2023: $747 · 2024: $830 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $924.73 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $481.60 | 2021-2024 | Linzess, Creon, Vraylar |
| Exact Sciences Corporation | $302.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $256.18 | 2020-2024 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $206.76 | 2021-2024 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.23 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $157.99 | 2021-2022 | |
| Lilly USA, LLC | $140.08 | 2021-2024 | Mounjaro |
| Pfizer INC. | $137.46 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $130.95 | 2019 | |
| Amarin Pharma, INC. | $119.39 | 2020 | |
| Gilead Sciences, INC. | $93.56 | 2024 | |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Amgen INC. | $54.54 | 2024 | Otezla, Repatha, Evenity |
| Insmed, INC. | $52.81 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Indivior INC. | $25.20 | 2024 | Sublocade |
| Celgene Corporation | $21.40 | 2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $19.87 | 2023 | |
| Alkermes, INC. | $18.19 | 2023 | Aristada, Lybalvi |
| Novo Nordisk INC | $14.41 | 2024 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $14.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.